# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

Konverge 20 mg/5 mg film-coated tablets

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Konverge 20 mg/5 mg film-coated tablets:

Each film-coated tablet of Konverge contains 20 mg of olmesartan medoxomil and 5 mg of amlodipine (as amlodipine besilate).

For the full list of excipients see section 6.1.

## 3 PHARMACEUTICAL FORM

Film-coated tablet

*Product imported from Portugal and Greece:*
White, round, film-coated tablet with C73 debossed on one side.

## 4 CLINICAL PARTICULARS

As per PA0865/017/001

## 5 PHARMACOLOGICAL PROPERTIES

As per PA0865/017/001

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Tablet core:
Starch, pregelatinised maize
Silicified microcrystalline cellulose (microcrystalline cellulose with colloidal silicon dioxide)
Croscarmellose sodium
Magnesium stearate

Tablet coat:
Polyvinyl alcohol
Macrogol 3350
Talc
Titanium dioxide (E171)

### 6.2 Incompatibilities

Not applicable.

**6.3 Shelf life**

The shelf-life expiry date of this product shall be the date shown on the container and outer package of the product on the market in the country of origin.

**6.4 Special precautions for storage**

This medicinal product does not require any special storage conditions.

**6.5 Nature and contents of container**

Blister pack containing 28 film-coated tablets in a cardboard carton.

**6.6 Special precautions for disposal and other handling**

No special requirements.

**7 PARALLEL PRODUCT AUTHORISATION HOLDER**

PCO Manufacturing Ltd.
Unit 10, Ashbourne Business Park
Rath
Ashbourne
Co. Meath
Ireland

**8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA0465/313/003

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 2nd August 2013

**10 DATE OF REVISION OF THE TEXT**

October 2021